Repertoire Immune Medicines

5 (602) · € 18.50 · En Stock

Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function in autoimmune disease. Our proprietary DECODE platform is designed to provide a comprehensive understanding of the full repertoire of interactions between T cell receptors and their antigen targets that take place when diseased cells are present. This complex and intricate biological process is known as the immune synapse. We believe the ability to decipher these interactions represents one of the greatest opportunities for innovation in medical science. Repertoire's team operates from sites in Cambridge, Massachusetts and Zurich, Switzerland and uses its DECODE technology to rationally design treatments for cancers, autoimmune disorders and infectious diseases. To learn more about Repertoire Immune Medicines, please visit our website: www.repertoire.com.

Repertoire Immune Medicines (@RepertoireIM) / X

Repertoire Immune Medicines (@RepertoireIM) / X

Susan Hockfield, Ph.D., MIT President Emerita, Joins Repertoire Immune Medicines Board of Directors

Repertoire Immune Medicines (@RepertoireIM) / X

Chutes & Ladders—Repertoire Immune Medicines, buzzing from $189M series B, taps Celgene vet as CMO

Leadership • Repertoire Immune Medicines

Anthony Coyle - Repertoire Immune Medicines

Home • Repertoire Immune Medicines

Leadership • Repertoire Immune Medicines

Repertoire Immune Medicines on X: Repertoire Immune Medicines enters collaboration on novel antigen discovery and T cell receptor research in multiple sclerosis. Read more here: #multiplesclerosis #MS #biotechnews